**Pylorus-Preserving Gastrectomy for Gastric Cancer**

Seung-Young Oh¹, Hyuk-Joon Lee¹,², and Han-Kwang Yang¹,²

¹Department of Surgery and ²Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

Pylorus-preserving gastrectomy (PPG) is a function-preserving surgery for the treatment of early gastric cancer (EGC), aiming to decrease the complication rate and improve postoperative quality of life. According to the Japanese gastric cancer treatment guidelines, PPG can be performed for cT1N0M0 gastric cancer located in the middle-third of the stomach, at least 4.0 cm away from the pylorus. Although the length of the antral cuff gradually increased, from 1.5 cm during the initial use of the procedure to 3.0 cm currently, its optimal length still remains unclear. Standard procedures for the preservation of pyloric function, infra-pyloric vessels, and hepatic branch of the vagus nerve, make PPG technically more difficult and raise concerns about incomplete lymph node dissection. The short- and long-term oncological and survival outcomes of PPG were comparable to those for distal gastrectomy, but with several advantages such as a lower incidence of dumping syndrome, bile reflux, and gallstone formation, and improved nutritional status. Gastric stasis, a typical complication of PPG, can be effectively treated by balloon dilatation and stent insertion. Robot-assisted pylorus-preserving gastrectomy is feasible for EGC in the middle-third of the stomach in terms of the short-term clinical outcome. However, any benefits over laparoscopy-assisted PPG (LAPPG) from the patient’s perspective have not yet been proven. An ongoing Korean multicenter randomized controlled trial (KLASS-04), which compares LAPPG and laparoscopy-assisted distal gastrectomy for EGC in the middle-third of the stomach, may provide more clear evidence about the advantages and oncologic safety of PPG.

**Key Words:** Pylorus-preserving gastrectomy; Stomach neoplasms; Review

**Introduction**

Due to the initiation of health screening programs in East Asian countries, including Korea and Japan, the proportion of early gastric cancer (EGC) has been increasing.¹ With the excellent outcomes obtained after early treatment of gastric cancer, surgeons are now recognizing postoperative quality of life (QOL) to be as important to consider as survival for these patients.²³

Two surgical approaches are widely used for the treatment of EGC: laparoscopic surgery and function-preserving surgery. Laparoscopic gastrectomy is widely used to manage gastric cancer because of the benefits of the minimally invasive approach, including less postoperative pain, better cosmetic results, early recovery of bowel function, and a rapid return to normal activity.²⁴ The oncologic outcomes of laparoscopic gastrectomy for EGC have been found to be comparable.⁶ The Korean multicenter randomized controlled trial (RCT) (KLASS-01 study) recently reported that the surgical morbidity rate, particularly the wound complication rate, had decreased in cases undergoing laparoscopic gastrectomy compared with those undergoing open surgery.⁷ Thus, laparoscopic gastrectomy is considered as one of the standard procedures for EGC.

In function-preserving surgery, there are several methods for reducing the surgical extent to improve postoperative functional outcomes without compromising oncologic safety, such as pylorus-preserving gastrectomy (PPG), proximal gastrectomy, sentinel node navigation surgery, and vagus nerve-preserving.
Among these techniques, PPG was initially introduced by Maki et al. for the treatment of peptic ulcers, and was subsequently applied in gastric cancer in Japan and Korea. Although several retrospective case–control studies have described the functional benefits of PPG over distal gastrectomy (DG), a multicenter RCT has not yet been conducted to provide high quality evidence supporting PPG.

In the present review, we describe the current status of PPG, the technical information, and advantages and limitations. We also briefly introduce our recent multicenter RCT that compares laparoscopic PPG and laparoscopic DG (KLASS-04 study).

### Methods

A PubMed search was conducted using the keywords ‘pylorus-preserving gastrectomy’ AND ‘gastric cancer’ for all articles published up to February 2016; only articles written in English were considered. For the analysis, meta-analyses and RCTs were preferentially reviewed. Prospective cohort studies and retrospective case–control studies were also reviewed.

### Indications and Surgical Techniques

#### 1. Indications

The indications for PPG in several centers are EGCs located in the middle-third of the stomach with no evidence of regional lymph node (LN) metastasis. According to the Japanese gastric cancer treatment guidelines, PPG is indicated for the treatment of cT1N0M0 gastric cancers in the middle-third of the stomach, at least 4.0 cm away from the pylorus.

#### 2. Length of the antral cuff

The distance from the lesion to the pylorus needs to be carefully considered as a short antral cuff length may lead to postoperative gastric stasis, a typical complication of PPG. When PPG was initially performed in the treatment of gastric cancer, surgeons usually maintained an antral cuff length of 1.5 cm. With this antral cuff length, incidence of immediate postoperative delayed gastric emptying (DGE) was reported to range between 23% and 40%. The relationship between the length of the antral segment and the incidence of DGE was investigated by Nakane et al. in 2002. In that study, the authors found that the incidence of DGE was 35.0% (7/20) in patients with an antral cuff length of 1.5 cm and only 10.0% (1/10) in patients with an antral cuff length of 2.5 cm, at 1 year after surgery.

### Table 1. Early experiences of pylorus-preserving gastrectomy

| Author         | Institute                  | No. of cases | Year        | Pyloric branch of the vagus nerve & RGA | Length of the antral segment (cm) |
|----------------|----------------------------|--------------|-------------|----------------------------------------|----------------------------------|
| Kodama et al.  | Akita University           | 35           | 1989–1991   | Preserved                              | 1.5                              |
| Zhang et al.   | University of Tokyo        | 15           | 1993–1995   | Divided                                | 1.5                              |
| Imada et al.   | Yokohama University        | 20           | 1992–1996   | Preserved                              | 1.5                              |
| Tomita et al.  | Nihon University           | 10           | 1993–1996   | Divided                                | 1.5                              |
| Nakane et al.  | Kansai University          | 30           | 1993–1999   | Preserved                              | 1.5 versus 2.5                    |
| Hotta et al.   | Wakayama University        | 19           | 1995–1998   | Preserved                              | 1.5                              |
| Ohya et al.    | Gumma University           | 13           | 1995–1998   | Preserved                              | 2.0                              |
| Nunobe et al.  | National Cancer Center     | 194          | 1993–1999   | Preserved                              | 2.5–6.0                          |
| Nagano et al.  | Fukui University           | 72           | 1991–2000   | Preserved                              | -                                |
| Nishikawa et al.| Osaka University           | 12           | 1997–2000   | Preserved                              | 1.5                              |
| Urushihara et al.| Yoshida General Hospital  | 26           | 1998–2002   | Preserved                              | 3.0                              |
| Park et al.    | Seoul National University  | 22           | 1999–2003   | Preserved                              | 3.0                              |
| Morita et al.  | National Cancer Center     | 611          | 1995–2004   | Preserved                              | 2.0                              |
| Tomikawa et al.| Fukuoka City Hospital      | 9            | 2004–2007   | Preserved                              | 3.0                              |
| Lee et al.     | Osaka Medical College      | 12           | 2000–2009   | NA                                     | ≥4.0                             |

RGA = right gastric artery; NA = not available.
et al. reported an incidence of DGE of 6% to 8% among 90 patients after PPG in whom vagus innervation and blood flow to the pylorus were preserved and the antral cuff length was maintained at 3 cm. In subsequent studies, the length of the antral cuff has tended to be longer than that used during the initial period (Table 1). However, a Japanese group did not identify antral cuff length as a key factor of the PPG technique, reporting comparable postoperative outcomes among a group of patients with an antral cuff length ≤3 cm and a group of patients with an antral cuff length >3 cm. Considering a sufficient distal resection margin of >1 cm for EGC in addition to the length of the antral cuff, the distance from the lesion to the pylorus should be maintained at >4.0 cm. Although guidelines suggest that the minimum distance from the lesion to the pylorus should be 4.0 cm, the optimal length for the antral cuff remains unclear yet.

3. Lymph node metastasis around the pylorus

An important factor that should be considered prior to performing a PPG is the likelihood of metastasis to LN station 5. This is particularly important as the LN dissection of station 5 is usually omitted during PPG in order to preserve the hepatic branch of the vagus nerve. A review of PPGs performed at 144 institutions in Japan indicated that dissection of LN station 5 was not performed in 53 institutions (36.8%) and was partially performed in 81 institutions (56.2%). At our institution, which is one of the institutions that actively performs PPG, dissection of LN station 5 was performed in only 50% of cases of PPG between 2003 and 2006. In addition to LN station 5, there is also a likelihood of incomplete LN dissection of station 6 during skeletonization of the infra-pyloric artery. For these reasons, the presence or absence of LN metastasis should be carefully evaluated preoperatively using endoscopic ultrasonography and computed tomography (CT). The depth of invasion should also be evaluated, as the probability of LN metastasis increases as the depth of the lesion increases. Hence, PPG should only be considered only for patients with a cT1N0M0 gastric cancer.

4. Techniques for preservation of the pylorus

Although there are minor differences in the surgical techniques according to specific surgeons, the standard technique for PPG includes preservation of the infra-pyloric vessels and the hepatic branch of the vagus nerve for structural and functional preservation of the pylorus. According to a study by Haruta et al., the infra-pyloric artery originates from the anterior superior pancreatoduodenal artery (distal type, 64.2% of cases), the right gastroepiploic artery (caudal type, 23.1% of cases), or the gastroduodenal artery (proximal type, 12.7% of cases). During dissection of LN station 6, the right gastroepiploic artery is ligated at its root in the distal or proximal types. For cases with a caudal type, the right gastroepiploic artery is ligated at a location distal to the origin of the infra-pyloric artery. The hepatic branch of the vagus nerve that innervates the pylorus usually follows the course of the supra-pyloric LNs (LN station 5) and should be preserved to maintain the motility of the pylorus. In the early years of PPG, surgeons commonly attempted to completely dissect the supra-pyloric LNs. However, today, most surgeons prefer to focus on preservation of the vagus nerve, rather than on supra-pyloric LN dissection during PPG.

5. Laparoscopic pylorus-preserving gastrectomy

As most patients who undergo PPG are usually diagnosed with EGC, laparoscopy-assisted pylorus-preserving gastrectomy (LAPPG) is commonly used. Although the operation time is longer in LAPPG than in conventional PPG, LAPPG provides several benefits over PPG, including reduced intraoperative blood loss and postoperative pain, as well as a faster recovery. Moreover, because LAPPG serves as combination of minimally invasive surgery and function-preserving surgery, LAPPG may appear as an attractive treatment option for patients. Both extra-corporeal and intra-corporeal methods can be used for anastomosis in LAPPG. For the extra-corporeal method, a hand-sewn anastomosis is usually used, which generally involves an approximately 5.0 cm midline incision after mobilization of the stomach with LN dissection. The distal part of the stomach is retracted through the incision and resected first. After the resection of the proximal part of the stomach, a hand-sewn gastro-gastrostomy is performed. Intra-corporeal anastomosis methods using linear staplers have only recently been introduced. For intra-corporeal anastomosis, transection of the stomach in the sagittal direction (i.e., posterior to anterior direction), rather than in the transverse direction (i.e., greater curvature to lesser curvature direction), can facilitate the alignment of the linear staplers. After resection of the distal and proximal parts of the stomach, one arm of a 60 mm linear stapler is inserted into each gastric remnant through the gastrotomy on the
greater curvature side corner. The stapler has to be fired between the posterior walls on either side, and then the remaining gastrostomy can be closed using further staplers.

**Clinical Outcomes**

1. **Complications**

With regard to the short-term outcomes of PPG, Shibata et al.\(^3\) compared PPG and DG and our group compared LAPPG and laparoscopy-assisted DG (LADG).\(^1\) Both studies indicated that the postoperative hospital stay, postoperative complications, and mortality did not differ between patients undergoing PPG and DG, regardless of the approach.

In a study performed with 307 patients who underwent LAPPG by Jiang et al.,\(^3\) the overall complication rate was 17.3% (53/307) including a major complication rate (grade>IIIa, Clavien–Dindo classification) of only 1.3% (4/307).\(^3\) In another study of complications (again, according to the Clavien–Dindo classification) of 116 patients who underwent LAPPG, the overall complication rate was 14.7% (17/116) and major complications, grade>IIIa, were found in 10 patients (8.6%).\(^1\) In both studies, the most common complication was associated with postoperative impairment in pyloric function: gastric stasis was present in 6.2% in the former study and DGE in 7.8% in the latter.

2. **Oncologic safety**

Preservation of the vessels and nerves in order to maintain pyloric function may result in insufficient LN dissection at LN stations 5, 6, and 12a, which could consequently compromise the radicality of the curative gastrectomy for gastric cancer. According to the Japanese gastric cancer treatment guidelines (ver. 3), D1+ lymphadenectomy should be performed for patients with cT1N0.\(^1\) LN dissection of station 6 with infra–pyloric artery preservation is a relatively easy technique, and LN station 12a is considered to be beyond the D1+ level in patients with cT1N0M0. However, LN station 5 is considered to be D1 level. In PPG, dissection of LN station 5 is omitted to preserve the hepatic branch of the vagus nerve and preserve pyloric function. This could lead to incomplete D1 LN dissection, which is associated with concerns regarding oncologic safety.

In a study about a new index evaluating the therapeutic value of LN dissection for gastric cancer, Sasako et al.\(^4\) reported that the index (estimated via multiplication of the incidence of metastasis and the 5-year survival rate of patients with metastasis to LN station 5) was only 0.8 in patients with cancer of the middle-third of the stomach. In particular, a few studies have also focused on the probability of metastasis to LN station 5 from EGC of middle-third of the stomach. Kodera et al.\(^4\) reported that the metastasis rate to LN station 5 was <5% and our group reported that the metastasis rate to LN station 5 was 4.2% (52/1,245) (Fig. 1).\(^4\)

---

**Fig. 1.** Station 5 and 6 lymph node metastases of gastric cancer in the middle-third of the stomach. Kong et al.\(^3\) examined the metastasis rate to each lymph node (LN) station in 1,802 patients with gastric cancer who underwent curative subtotal gastrectomy. Among patients with a distal resection margin (DRM) <6.0 cm, the metastasis rate to LN station 5 was 0.3% (1 of 317) for patients with a T1a cancer, 2.7% (8 of 293) for patients with a T1b cancer, and 8.0% (10 of 125) for patients with a T2a cancer. For metastasis to LN station 6, the rate was 0.6% (2 of 330) for patients with a T1a cancer, 9.5% (28 of 294) for patients with a T1b cancer, and 25.4% (33 of 130) for patients with a T2a cancer. M = mucosa; SM = submucosa; PM = proper muscle.
In both studies, most of the patients with LN metastasis in station 5 were finally confirmed as having at least T2 cancer after surgeries, whereas the metastasis rates to LN station 5 were very low for T1 cancer. Furthermore, Hiki et al. and Nunobe et al. reported supra-pyloric LN metastasis rates of 0.2% and 0.5%, respectively, for T1 cancer located in the middle-third of the stomach. Our group reported that LN dissection during PPG was adequate by using the Manyama index, which is calculated as the sum of the likelihood of undissected nodal disease in each LN station.

3. Survival and recurrence

The long-term outcomes of PPG have been evaluated in many retrospective studies. Hiki et al. reported that the 5-year survival rate of patients who underwent PPG for a cT1N0 gastric cancer was 98% with no cases of recurrence. Morita et al. reported a 5-year survival rate of 96.3%, with 5 cases of recurrence, among patients who underwent PPG for EGC. Our group recently reported a 3-year recurrence-free survival rate of 98.2% for LAPPG for EGC, which is comparable with the rate for LADG. One of two meta-analyses on PPG also reported that a 5-year survival rates were similar in patients underwent PPG or DG.

Advantages and Pitfalls

The benefits of PPG, when compared with DG, include the lower incidence of dumping syndrome, bile reflux, and gallstone formation, and better nutritional advantages such as a relatively small body weight change. A large scale retrospective study on dumping syndrome after gastrectomy involving 1,153 patients found that PPG was a preventive factor for early and late dumping syndromes. In another questionnaire-based study on QOL after gastrectomy, PPG was found to have significantly lower scores in terms of diarrhea as well as dumping syndrome, when compared with DG. In addition, the study from our institution reported a lower incidence of gallstone formation among patients who underwent LAPPG (0%) compared with those who underwent LADG (6.5%). The study also showed that patients who underwent LAPPG had a better nutritional status as compared with those who underwent LADG, including a smaller decrease in serum protein levels, serum albumin levels, and abdominal fat. Two recently published meta-analyses on PPG specifically evaluated the postoperative QOL among patients who underwent PPG or DG. Both the meta-analysis conducted by Song et al. involving 1,774 patients in 15 studies and the meta-analysis conducted by Xiao et al. involving 1,213 patients in 16 studies reported PPG to be a preventive factor of dumping syndrome, bile reflux, gastritis, and gallstone formation, while acting as a beneficial factor in weight regain.

As mentioned previously, gastric stasis is a typical complication of PPG. The pathophysiologic mechanism of gastric stasis after PPG has not been definitively identified, but it is known to be caused to some extent by anastomotic edema and neurologic dysfunction due to intraoperative damage. During initial experiences with PPG, the incidence of gastric stasis was as high as 40%. Recently published studies have reported the incidence of gastric stasis or DGE after PPG of 6.2% to 10.3%. However, this value is still considered to be high, given that the rate of these complications in DG is approximately 1.0%.

Gastric stasis can be easily diagnosed based on a combination of symptoms, such as post-prandial epigastric fullness or indigestion, and simple imaging, such as radiography or an upper gastrointestinal series. Patients who developed gastric stasis after PPG may show improvement via conservative management and radiological interventions. Bae et al. reported that the standardization of the surgical procedure for LAPPG in order to preserve blood flow and the hepatic branch of the vagus nerve can reduce the severity of gastric stasis. Moreover, cases of mild gastric stasis with a Clavien–Dindo classification grade ≤II responded to gastric balloon dilatation. However, in 26.7% (12/45) of patients who developed gastric stasis after PPG, gastric balloon dilatation was not sufficient to improve the obstructive symptoms due to recoiling of the pyloric canal. In these patients, retrievable stent insertion could resolve the obstructive symptoms. The mean duration of stent retention was 10.4±5.0 days and none of the patients showed a recurrence of gastric stasis over 26.2 months of follow-up. Among 50 cases of balloon dilatation, only 1 case of a transmural tear was noted, and among 12 stent insertions, 3 cases of stent migration were observed. This finding is important for the determination of an effective treatment option for gastric stasis due to pyloric spasm after PPG. However, considering the relatively invasive properties of the procedure itself and the possibility of stent migration, stent insertion should only be performed after balloon dilatation has been attempted.
Robotic Surgery

Robotic surgery is reported to have several benefits including three-dimensional and highly magnified imaging, a steady fixed camera, and absence of a surgeon’s tremors when compared with laparoscopic surgery. However, the benefits of robotic surgery in patients with gastric cancer remain controversial. In a recently published multicenter prospective case–matched study by the Korean Robot Gastrectomy Study Group of the KLASS, robotic gastrectomy was not found to be superior to laparoscopic gastrectomy in terms of perioperative clinical outcomes, even though it may provide a superior operating environment. Although several studies on robotic surgery for gastric cancer have been published, studies focused on robot assisted pylorus-preserving gastrectomy (RAPPG) are rare and there is no RCT comparing RAPPG and LAPPG thus far. Recently, Han et al. reported on the surgical outcomes of RAPPG for gastric cancer. Based on a propensity score matching analysis of RAPPG and LAPPG, there were no differences in complication rates or the number of examined LNs between the two groups. The only difference between RAPPG and LAPPG was the operation time, which was longer in RAPPG than in LAPPG (258.3 versus 193.9 minutes). As such, RAPPG may provide another treatment option for EGC in the middle–third of the stomach; however, the benefits of RAPPG over LAPPG from patients’ perspective are yet to be determined.

KLASS-04 Study: A Multicenter Prospective Randomized Controlled Trial

Although a few studies have evaluated the optimal surgical procedures to treat EGC of the middle–third of the stomach, comparing LAPPG and LADG, most studies on PPG have been performed at a single center with a limited number of patients and in a retrospective manner. For the application of LAPPG in the clinical setting, it is essential to first perform a comparative analysis of the short- and long-term outcomes from a large volume of prospective randomized data. In order to determine whether the postoperative QOL and nutritional status are better, and if survival is comparable after LAPPG, the KLASS group has initiated a multicenter RCT (KLASS-04 study) to compare LAPPG and LADG for EGC of the middle–third of the stomach (NCT No.02595086).

A total of 256 patients, diagnosed with a cT1N0M0 primary gastric adenocarcinoma located in the middle–third of the stomach by endoscopic ultrasonography or CT, will be enrolled.

Table 2. Indications and contraindications for KLASS-04 study

| Indications                                      | Contraindications                                                                 |
|------------------------------------------------|----------------------------------------------------------------------------------|
| 1. Age (yr) ≤ 80                               | ① Pyloric deformity due to ulcerative disease                                    |
| 2. Histologically proven gastric adenocarcinoma | ② History of gastric surgery (e.g., gastrojejunostomy or primary closure)        |
| 3. Performance status of 0 or 1 on the Eastern  | ③ Synchronous early gastric cancer or adenoma in the antrum                      |
| Cooperative Oncology Group scale                | ④ Prior treatment with chemotherapy or radiotherapy against early gastric cancer |
| 4. American Society of Anesthesiologists class  | ⑤ Need for combined resection (e.g., cholecystectomy)                            |
| ≤ 3                                            | ⑥ History of prior treatment (e.g., surgery, chemotherapy, or radiotherapy)     |
| 5. cT1N0M0 (by endoscopic ultrasonography or     | ⑦ Lack of decision-making capacity                                               |
| computed tomography scan)                       | ⑧ Pregnant or breast-feeding women                                               |
| ⑥ Located at the middle-third of the stomach   | ⑨ Currently involved or participated in another clinical trial within the last   |
| at least 5 cm away from the pylorus and resectable by distal gastrectomy | 6 months                                                                        |
| ⑦ Written informed consent                      |                                                                                 |


patients in each group) (Table 2). The primary endpoint is the incidence of dumping syndrome, assessed using the Sigstad score (≥7) at 1 year after surgery. The secondary endpoints are: the 3-year relapse-free survival and overall survival; the 30-day operative morbidity and mortality; changes in body weight and fat volume on abdominal CT; changes in hemoglobin, protein, albumin, and pre-albumin levels; symptoms and QOL measurement using the JSGIS-Q, EORTC C30, and STO22; the incidence of gallstones; and the gross and microscopic findings on gastroscopy (Fig. 2).

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Kim YG, Kong SH, Oh SY, Lee KG, Suh YS, Yang JY, et al. Effects of screening on gastric cancer management: comparative analysis of the results in 2006 and in 2011. J Gastric Cancer 2014;14:129-134.
2. Kim YW, Baik YH, Yun YH, Nam BH, Kim DH, Choi JJ, et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 2008;248:721-727.
3. Ahn HS, Lee HJ, Yoo MW, Jeong SH, Park DJ, Kim HH, et al. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg 2011;98:255-260.
4. Adachi Y, Suematsu T, Shiraishi N, Katsuta T, Morimoto A, Kitano S, et al. Quality of life after laparoscopy-assisted Billroth I gastrectomy. Ann Surg 1999;229:49-54.
5. Lee HJ, Yang HK. Laparoscopic gastrectomy for gastric cancer. Dig Surg 2013;30:132-141.
6. Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol 2014;32:627-633.
7. Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg 2016;263:28-35.
8. Saito T, Kurokawa Y, Takiguchi S, Mori M, Doki Y. Current status of function-preserving surgery for gastric cancer. World J Gastroenterol 2014;20:17297-17304.
9. Maki T, Shiratori T, Hatafuku T, Sugawara K. Pylorus-preserving gastrectomy as an improved operation for gastric ulcer. Surgery 1967;61:838-845.
10. Nunobe S, Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Symptom evaluation of long-term postoperative outcomes after pylorus-preserving gastrectomy for early gastric cancer. Gastric Cancer 2007;10:167-172.
11. Park DJ, Lee HJ, Jung HC, Kim WH, Lee KU, Yang HK. Clinical outcome of pylorus-preserving gastrectomy in gastric cancer in comparison with conventional distal gastrectomy with Billroth I anastomosis. World J Surg 2008;32:1029-1036.
12. Suh YS, Han DS, Kong SH, Kwon S, Shin CI, Kim WH, et al. Laparoscopy-assisted pylorus-preserving gastrectomy is better than laparoscopy-assisted distal gastrectomy for middle-third early gastric cancer. Ann Surg 2014;259:485-493.
13. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14:113-123.
14. Kodama M, Koyama K, Chida T, Arakawa A, Tur G. Early postoperative evaluation of pylorus-preserving gastrectomy for gastric cancer. World J Surg 1995;19:456-460; discussion 61.
15. Imada T, Rino Y, Takahashi M, Suzuki M, Tanaka J, Shiozawa M, et al. Postoperative functional evaluation of pylorus-
preserving gastrectomy for early gastric cancer compared with conventional distal gastrectomy. Surgery 1998;123:165-170.
16. Zhang D, Shimoyama S, Kaminishi M. Feasibility of pylorus-preserving gastrectomy with a wider scope of lymphadenectomy. Arch Surg 1998;133:993-997.
17. Nakane Y, Michiura T, Inoue K, Sato M, Nakai K, Yamamichi K. Length of the antral segment in pylorus-preserving gastrectomy. Br J Surg 2002;89:220-224.
18. Nunobe S, Hiki N, Fukunaga T, Tokunaga M, Ohyama S, Seto Y, et al. Laparoscopic-assisted pylorus-preserving gastrectomy: preservation of vagus nerve and infrapyloric blood flow induces less stasis. World J Surg 2007;31:2335-2340.
19. Hotta T, Taniguchi K, Kobayashi Y, Johata K, Sahara M, Naka T, et al. Postoperative evaluation of pylorus-preserving procedures compared with conventional distal gastrectomy for early gastric cancer. Surg Today 2001;31:774-779.
20. Lee SW, Bouras G, Nomura E, Yoshinaka R, Tokuhara T, Nitta T, et al. Intracorporeal stapled anastomosis following laparoscopic segmental gastrectomy for gastric cancer: technical report and surgical outcomes. Surg Endosc 2010;24:1774-1780.
21. Morita S, Katai H, Saka M, Fukagawa T, Sano T, Sasako M. Outcome of pylorus-preserving gastrectomy for early gastric cancer. Br J Surg 2008;95:1131-1135.
22. Nagano H, Ohyama S, Sakamoto Y, Ohta K, Yamaguchi T, Muto T, et al. The endoscopic evaluation of gastritis, gastric remnant residue, and the incidence of secondary cancer after pylorus-preserving and transverse gastrectomies. Gastric Cancer 2004;7:54-59.
23. Nishikawa K, Kawahara H, Yumiba T, Nishida T, Inoue Y, Ito T, et al. Functional characteristics of the pylorus in patients undergoing pylorus-preserving gastrectomy for early gastric cancer. Surgery 2002;131:613-624.
24. Ohya T, Ohwada S, Iesato H, Takeyoshi I, Kawashima Y, Ogawa T, et al. Jejunal pouch interposition after pylorus-preserving gastrectomy. J Surg Res 1999;86:177-182.
25. Tomikawa M, Korenaga D, Akahoshi T, Kohshi K, Sugimachi K, Nagao Y, et al. Quality of life after laparoscopy-assisted pylorus-preserving gastrectomy: an evaluation using a questionnaire mailed to the patients. Surg Today 2012;42:625-632.
26. Tomita R, Fujisaki S, Tanjoh K. Pathophysiological studies on the relationship between postgastrectomy syndrome and gastric emptying function at 5 years after pylorus-preserving distal gastrectomy for early gastric cancer. World J Surg 2003;27:725-733.
27. Urushihara T, Sumimoto K, Shimokado K, Kuroda Y. Gastric motility after laparoscopically assisted distal gastrectomy, with or without preservation of the pylorus, for early gastric cancer, as assessed by digital dynamic x-ray imaging. Surg Endosc 2004;18:964-968.
28. Morita S, Sasa M, Saka M, Fukagawa T, Sano T, Katai H. Correlation between the length of the pyloric cuff and postoperative evaluation after pylorus-preserving gastrectomy. Gastric Cancer 2010;13:109-116.
29. Shibata C, Sajo F, Kakyo M, Kinouchi M, Tanaka N, Sasaki I, et al. Current status of pylorus-preserving gastrectomy for the treatment of gastric cancer: a questionnaire survey and review of literatures. World J Surg 2012;36:858-863.
30. Kong SH, Kim JW, Lee HJ, Kim WH, Lee KU, Yang HK. The safety of the dissection of lymph node stations 5 and 6 in pylorus-preserving gastrectomy. Ann Surg Oncol 2009;16:3252-3258.
31. Haruta S, Shinohara H, Ueno M, Udagawa H, Sakai Y, Uyama I. Anatomical considerations of the infrapyloric artery and its associated lymph nodes during laparoscopic gastric cancer surgery. Gastric Cancer 2015;18:876-880.
32. Sawai K, Takahashi T, Fujioka T, Minato H, Taniguchi H, Yamaguchi T. Pylorus-preserving gastrectomy with radical lymph node dissection based on anatomical variations of the infrapyloric artery. Am J Surg 1995;170:285-288.
33. Hiki N, Shimoyama S, Yamaguchi H, Kubota K, Kaminishi M. Laparoscopy-assisted pylorus-preserving gastrectomy with quality controlled lymph node dissection in gastric cancer operation. J Am Coll Surg 2006;203:162-169.
34. Tanaka N, Katai H, Saka M, Morita S, Fukagawa T. Laparoscopy-assisted pylorus-preserving gastrectomy: a matched case-control study. Surg Endosc 2011;25:114-118.
35. Hiki N, Kaminishi M. Pylorus-preserving gastrectomy in gastric cancer surgery: open and laparoscopic approaches. Langenbecks Arch Surg 2005;390:442-447.
36. Kumagai K, Hiki N, Nunobe S, Sekikawa S, Chiba T, Kiyokawa T, et al. Totally laparoscopic pylorus-preserving gastrectomy for early gastric cancer in the middle stomach: technical report and surgical outcomes. Gastric Cancer 2015;18:183-187.
37. Shibata C, Shiiba KL, Funayama Y, Ishii S, Fukushima K, Mizoi T, et al. Outcomes after pylorus-preserving gastrectomy for early gastric cancer: a prospective multicenter trial. World J Surg 2004;28:857-861.
38. Jiang X, Hiki N, Nunobe S, Fukunaga T, Kumagai K, Nohara K,
et al. Postoperative outcomes and complications after laparoscopy-assisted pylorus-preserving gastrectomy for early gastric cancer. Ann Surg 2011;253:928-933.
39. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213.
40. Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995;82:346-351.
41. Kodera Y, Yamamura Y, Kanemitsu Y, Shimizu Y, Hirai T, Yasui K, et al. Lymph node metastasis in cancer of the middle-third stomach: criteria for treatment with a pylorus-preserving gastrectomy. Surg Today 2001;31:196-203.
42. Hiki N, Nunobe S, Kubota T, Jiang X. Function-preserving gastrectomy for early gastric cancer. Ann Surg Oncol 2013;20:2683-2692.
43. Yoo MW, Park DJ, Ahn HS, Jeong SH, Lee HJ, Kim WH, et al. Evaluation of the adequacy of lymph node dissection in pylorus-preserving gastrectomy for early gastric cancer using the maruyama index. World J Surg 2010;34:291-295.
44. Hiki N, Sano T, Fukunaga T, Ohyama S, Tokunaga M, Yamaguchi T. Survival benefit of pylorus-preserving gastrectomy in early gastric cancer. J Am Coll Surg 2009;209:297-301.
45. Xiao XM, Guo C, Yin W, Yu WH, Qi F, Liu T. Pylorus-preserving versus distal subtotal gastrectomy for surgical treatment of early gastric cancer: a meta-analysis. Hepatogastroenterology 2014;61:870-879.
46. Isozaki H, Okajima K, Momura E, Ichinona T, Fujii K, Izumi N, et al. Postoperative evaluation of pylorus-preserving gastrectomy for early gastric cancer. Br J Surg 1996;83:266-269.
47. Mine S, Sano T, Tsutsumi K, Murakami Y, Ehara K, Saka M, et al. Large-scale investigation into dumping syndrome after gastrectomy for gastric cancer. J Am Coll Surg 2010;211:628-636.
48. Fujita J, Takahashi M, Urushihara T, Tanabe K, Kodera Y, Yumiba T, et al. Assessment of postoperative quality of life following pylorus-preserving gastrectomy and Billroth-I distal gastrectomy in gastric cancer patients: results of the nationwide postgastrectomy syndrome assessment study. Gastric Cancer 2016;19:302-311.
49. Song P, Lu M, Pu F, Zhang D, Wang B, Zhao Q. Meta-analysis of pylorus-preserving gastrectomy for middle-third early gastric cancer. J Laparoendosc Adv Surg Tech A 2014;24:718-727.
50. Fujita T. Outcome of pylorus-preserving gastrectomy for early gastric cancer (Br J Surg 2008;95:1131-1135). Br J Surg 2008;95:1429; author reply 1429-1430.
51. Bae JS, Kim SH, Shin CI, Joo I, Yoon JH, Lee HJ, et al. Efficacy of gastric balloon dilatation and/or retrievable stent insertion for pyloric spasms after pylorus-preserving gastrectomy: retrospective analysis. PLoS One 2015;10:e0144470.
52. Han DS, Suh YS, Ahn HS, Kong SH, Lee HJ, Kim WH, et al. Comparison of surgical outcomes of robot-assisted and laparoscopy-assisted pylorus-preserving gastrectomy for gastric cancer: a propensity score matching analysis. Ann Surg Oncol 2015;22:2323-2328.
53. Kim HI, Han SU, Yang HK, Kim YW, Lee HJ, Ryu KW, et al. Multicenter Prospective Comparative Study of Robotic Versus Laparoscopic Gastrectomy for Gastric Adenocarcinoma. Ann Surg 2016;263:103-109.